Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Kristijan Ramadan and his group published a new article in The EMBO Journal today. The article adds new detail to the story of how our cells repair damage to our DNA.

All day every day cells must detect and repair DNA damage. DNA damage comes in several forms, but the most dangerous and the most relevant for radiotherapy is DNA double strand breaks.

Repairing DNA damage is a team game, with a number of proteins coming together to regulate and carry out the repair. These proteins are vital for the repair, but accumulation of too much of these proteins will cause issues such as genome instability, which can promote both tumour genesis and tumour progression.

RING finger protein 8 (RNF8) is an integral part of the DNA repair process, but it must not be allowed to accumulate in a cell.

Kristijan and his group have uncovered how the cell maintains just the right amount of RNF8. A combination of two proteins, p97 and ATX3 work together to adjust levels of RNF8. Inactivation of the p97-ATX3 combination prevents the cells from regulating the amount of RNF8 and makes the cells very sensitive to radiation.

Since many cancers have evolved to rely heavily on the DNA repair that RNF8 facilitates, this suggests an interesting target for cancer therapy. A target that should hurt cancer cells very much more than healthy ones.

 

 

Abhay Narayan Singh, Judith Oehler, Ignacio Torrecilla, Susan Kilgas, Shudong Li, Bruno Vaz, Claire Guérillon, John Fielden, Esperanza HernandezCarralero, Elisa Cabrera, Iain DC Tullis, Mayura Meerang, Paul R Barber, Raimundo Freire, Jason Parsons, Borivoj Vojnovic, Anne E Kiltie, Niels Mailand, Kristijan Ramadan. (2019) The p97–Ataxin 3 complex regulates homeostasis of the DNA damage response E3 ubiquitin ligase RNF8. EMBO J (2019): e102361

https://www.embopress.org/doi/10.15252/embj.2019102361

Similar stories

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.